ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2023 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/58983 |
Resumo: | Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Centro de Pesquisas Rene Rachou. Fundação Osvaldo Cruz, Rio de Janeiro, Brasil / 3Plataforma de Medicina Translacional, Fundação Oswaldo Cruz-Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil. |
| id |
CRUZ_770f9c542e5ad320999d8b0c99713c22 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/58983 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Castro, Julia T.Brito, RoryHojo-Souza, Natalia S.Azevedo, BárbaraSalazar, NataliaFerreira, Camila P.Junqueira, CarolineFernandes, Ana PaulaVasconcellos, RonnieCardoso, Jamille M.Soares, Rodrigo D. O. AguiarVieira, Paula M. A.Carneiro, Cláudia M.Valiate, BrunoToledo, CristianeSalazar, Andres M.Caballero, OtáviaLannes-Vieira, JoseliTeixeira, Santuza R.Reis, Alexandre B.Gazzinelli, Ricardo T.2023-06-09T13:34:16Z2023-06-09T13:34:16Z2023CASTRO, Julia T. et al. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease. Vaccines, v. 8; 81, p. 1 - 14, 2023.2076-393Xhttps://www.arca.fiocruz.br/handle/icict/5898310.1038/s41541-023-00676-0engNatureDoença de ChagasProteína quimérica ASP-2/Trans-sialidaseInduz imunidade protetoraEm modelos experimentaisDa doença de ChagasChagas diseaseASP-2/Trans-sialidase chimeric proteinInduces robust protective immunityIn experimental modelsASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCentro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Centro de Pesquisas Rene Rachou. Fundação Osvaldo Cruz, Rio de Janeiro, Brasil / 3Plataforma de Medicina Translacional, Fundação Oswaldo Cruz-Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Fundação Osvaldo Cruz. Centro de Pesquisas Rene Rachou., Belo Horizonte, MG, Brasil.Fundação Osvaldo Cruz. Centro de Pesquisas Rene Rachou., Belo Horizonte, MG, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil.Universidade Federal de São Paulo. São Paulo, SP, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Fundação Osvaldo Cruz. Centro de Pesquisas Rene Rachou. Belo Horizonte, MG, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil.Universidade Federal de São Paulo, São Paulo, SP, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Centro de Pesquisas Rene Rachou. Fundação Osvaldo Cruz, Rio de Janeiro, Brasil .Centro de Pesquisas Rene Rachou. Belo Horizonte, MG, Brasil.Oncovir, Inc, Washington, USA.Orygen, LTDA, Sao Paulo, SP, Brasil.Fundação Osvaldo Cruz, Rio de Janeiro, RJ, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil.Universidade Federal de Ouro Preto, Ouro Preto, MG, Brasil.Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Centro de Pesquisas Rene Rachou. Fundação Osvaldo Cruz, Belo Horizonte, MG, Brasil / Plataforma de Medicina Translacional, Fundação Oswaldo Cruz-Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil.Immunization with the Amastigote Surface Protein-2 (ASP-2) and Trans-sialidase (TS) antigens either in the form of recombinant protein, encoded in plasmids or human adenovirus 5 (hAd5) confers robust protection against various lineages of Trypanosoma cruzi. Herein we generated a chimeric protein containing the most immunogenic regions for T and B cells from TS and ASP-2 (TRASP) and evaluated its immunogenicity in comparison with our standard protocol of heterologous prime-boost using plasmids and hAd5. Mice immunized with TRASP protein associated to Poly-ICLC (Hiltonol) were highly resistant to challenge with T. cruzi, showing a large decrease in tissue parasitism, parasitemia and no lethality. This protection lasted for at least 3 months after the last boost of immunization, being equivalent to the protection induced by DNA/hAd5 protocol. TRASP induced high levels of T. cruzispecific antibodies and IFNγ-producing T cells and protection was primarily mediated by CD8+ T cells and IFN-γ. We also evaluated the toxicity, immunogenicity, and efficacy of TRASP and DNA/hAd5 formulations in dogs. Mild collateral effects were detected at the site of vaccine inoculation. While the chimeric protein associated with Poly-ICLC induced high levels of antibodies and CD4+ T cell responses, the DNA/hAd5 induced no antibodies, but a strong CD8+ T cell response. Immunization with either vaccine protected dogs against challenge with T. cruzi. Despite the similar efficacy, we conclude that moving ahead with TRASP together with Hiltonol is advantageous over the DNA/hAd5 vaccine due to pre-existing immunity to the adenovirus vector, as well as the cost-benefit for development and large-scale production.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALJoseliLannesVieira_etal_IOC_2023.pdfJoseliLannesVieira_etal_IOC_2023.pdfapplication/pdf6026365https://www.arca.fiocruz.br/bitstream/icict/58983/2/JoseliLannesVieira_etal_IOC_2023.pdf62a2387e405204ca93af1d4c14f56f5aMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/58983/1/license.txt5a560609d32a3863062d77ff32785d58MD51icict/589832023-09-04 11:10:23.491oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-04T14:10:23Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| title |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| spellingShingle |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease Castro, Julia T. Doença de Chagas Proteína quimérica ASP-2/Trans-sialidase Induz imunidade protetora Em modelos experimentais Da doença de Chagas Chagas disease ASP-2/Trans-sialidase chimeric protein Induces robust protective immunity In experimental models |
| title_short |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| title_full |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| title_fullStr |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| title_full_unstemmed |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| title_sort |
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease |
| author |
Castro, Julia T. |
| author_facet |
Castro, Julia T. Brito, Rory Hojo-Souza, Natalia S. Azevedo, Bárbara Salazar, Natalia Ferreira, Camila P. Junqueira, Caroline Fernandes, Ana Paula Vasconcellos, Ronnie Cardoso, Jamille M. Soares, Rodrigo D. O. Aguiar Vieira, Paula M. A. Carneiro, Cláudia M. Valiate, Bruno Toledo, Cristiane Salazar, Andres M. Caballero, Otávia Lannes-Vieira, Joseli Teixeira, Santuza R. Reis, Alexandre B. Gazzinelli, Ricardo T. |
| author_role |
author |
| author2 |
Brito, Rory Hojo-Souza, Natalia S. Azevedo, Bárbara Salazar, Natalia Ferreira, Camila P. Junqueira, Caroline Fernandes, Ana Paula Vasconcellos, Ronnie Cardoso, Jamille M. Soares, Rodrigo D. O. Aguiar Vieira, Paula M. A. Carneiro, Cláudia M. Valiate, Bruno Toledo, Cristiane Salazar, Andres M. Caballero, Otávia Lannes-Vieira, Joseli Teixeira, Santuza R. Reis, Alexandre B. Gazzinelli, Ricardo T. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Castro, Julia T. Brito, Rory Hojo-Souza, Natalia S. Azevedo, Bárbara Salazar, Natalia Ferreira, Camila P. Junqueira, Caroline Fernandes, Ana Paula Vasconcellos, Ronnie Cardoso, Jamille M. Soares, Rodrigo D. O. Aguiar Vieira, Paula M. A. Carneiro, Cláudia M. Valiate, Bruno Toledo, Cristiane Salazar, Andres M. Caballero, Otávia Lannes-Vieira, Joseli Teixeira, Santuza R. Reis, Alexandre B. Gazzinelli, Ricardo T. |
| dc.subject.other.en_US.fl_str_mv |
Doença de Chagas Proteína quimérica ASP-2/Trans-sialidase Induz imunidade protetora Em modelos experimentais Da doença de Chagas |
| topic |
Doença de Chagas Proteína quimérica ASP-2/Trans-sialidase Induz imunidade protetora Em modelos experimentais Da doença de Chagas Chagas disease ASP-2/Trans-sialidase chimeric protein Induces robust protective immunity In experimental models |
| dc.subject.en.en_US.fl_str_mv |
Chagas disease ASP-2/Trans-sialidase chimeric protein Induces robust protective immunity In experimental models |
| description |
Centro de Tecnologia em Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, Belo Horizonte, Brasil / Centro de Pesquisas Rene Rachou. Fundação Osvaldo Cruz, Rio de Janeiro, Brasil / 3Plataforma de Medicina Translacional, Fundação Oswaldo Cruz-Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brasil. |
| publishDate |
2023 |
| dc.date.accessioned.fl_str_mv |
2023-06-09T13:34:16Z |
| dc.date.available.fl_str_mv |
2023-06-09T13:34:16Z |
| dc.date.issued.fl_str_mv |
2023 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CASTRO, Julia T. et al. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease. Vaccines, v. 8; 81, p. 1 - 14, 2023. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/58983 |
| dc.identifier.issn.en_US.fl_str_mv |
2076-393X |
| dc.identifier.eissn.none.fl_str_mv |
10.1038/s41541-023-00676-0 |
| identifier_str_mv |
CASTRO, Julia T. et al. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease. Vaccines, v. 8; 81, p. 1 - 14, 2023. 2076-393X 10.1038/s41541-023-00676-0 |
| url |
https://www.arca.fiocruz.br/handle/icict/58983 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Nature |
| publisher.none.fl_str_mv |
Nature |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/58983/2/JoseliLannesVieira_etal_IOC_2023.pdf https://www.arca.fiocruz.br/bitstream/icict/58983/1/license.txt |
| bitstream.checksum.fl_str_mv |
62a2387e405204ca93af1d4c14f56f5a 5a560609d32a3863062d77ff32785d58 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009156925292544 |